川崎病静脉注射免疫球蛋白抵抗评分系统研究进展
Research progress of resistance score systems of intravenous immunoglobulin in children with Kawasaki disease
吴美 1王川2
作者信息
- 1. 610041成都,四川大学华西第二医院儿童心血管科;610041成都,四川大学华西第二医院出生缺陷与相关妇儿疾病教育部重点实验室;610041成都,四川大学华西临床医学院
- 2. 610041成都,四川大学华西第二医院儿童心血管科;610041成都,四川大学华西第二医院出生缺陷与相关妇儿疾病教育部重点实验室
- 折叠
摘要
自使用大剂量静脉注射免疫球蛋白(IVIG)治疗川崎病以来,川崎病患儿冠状动脉损伤发生率显著下降.但是,10％～20％患儿对首次IVIG治疗发生抵抗,并且这些患儿较IVIG治疗敏感患儿具有更显著冠状动脉损伤趋势.目前已有部分研究对川崎病IVIG抵抗进行系统评分,旨在早期预估川崎病患儿IVIG抵抗,并指导临床治疗.笔者拟就IVIG抵抗评分系统研究进展进行综述.
Abstract
The incidence of coronary artery lesions has decreased since high-dose intravenous immunoglobulin(IVIG) was applied in children with Kawasaki disease.However,almost 10％-20％ children with Kawasaki disease has the clinical features of resistance to first dose of IVIG therapy,and they were more likely of suffering from coronary artery lesions than the IVIG responders.There were several resistance score systems to evaluate IVIG resistance in Kawasaki disease,so as to predict and evaluate the response of IVIG therapy in early stage and guide clinical treatment timely.We summarized the literatures and research progress of IVIG resistance score systems in this review.
关键词
黏膜皮肤淋巴结综合征/免疫球蛋白类,静脉内/抵抗评分系统/儿童Key words
Mucocutaneous lymph node syndrome/Immunoglobulins, intravenous/Resistance score system/Child引用本文复制引用
基金项目
长江学者和创新团队发展计划(IRT0935)
四川省科技厅科技支撑计划项目(2014SZ0009)
四川省科技厅科技支撑计划项目(2016SZ0056)
四川省公益民生项目(2014SZ0149)
出版年
2017
NETL
NSTL
维普
万方数据